Literature DB >> 31097329

[Pharmacological management of neuropathic pain].

Hichem Bouchenaki1, Mélina Bégou2, Laurent Magy3, Rodolphe Hajj4, Claire Demiot5.   

Abstract

Neuropathic pain is defined as pain caused by a lesion or a disease affecting the somatosensory nervous system. Development of neuropathic pain is induced by many pathophysiological mechanisms affecting pain pathways. Neuropathic pain has diverse origins, making its management difficult, hence, many patients with neuropathic pain do not receive appropriate treatment. In 2015, a revision of the Neuropathic Pain Special Interest Group's (NeuPSIG) previous recommendations, based on a systematic review and meta-analysis, evaluated the efficacy of systemic and topical treatments of neuropathic pain. Treatments lines were established using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), which allows to rate the quality of evidence and the strength of recommendations. First line treatments are gabapentin and pregabalin, noradrenalin and serotonin reuptake inhibitors and tricyclic antidepressants. Capsaicin and lidocaine patches are second line treatments, tramadol and strong opioids are third line treatments. This work also highlighted molecules with inconclusive recommendations or non-recommended pharmacological treatments based on a low quality of evidence, a lack of efficacy or a bad safety profile. The objective of this paper is to present the different treatments and to detail their mechanisms of action.
Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Douleur neuropathique; Level of evidence; Neuropathic pain; Niveau de preuve; Recommandations; Recommendations

Mesh:

Substances:

Year:  2019        PMID: 31097329     DOI: 10.1016/j.therap.2019.04.003

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  4 in total

1.  LncRNA H19 secreted by umbilical cord blood mesenchymal stem cells through microRNA-29a-3p/FOS axis for central sensitization of pain in advanced osteoarthritis.

Authors:  Qinyan Yang; Yutong Yao; Daqiang Zhao; Haibo Zou; Chunyou Lai; Guangming Xiang; Guan Wang; Le Luo; Ying Shi; Yan Li; Maozhu Yang; Xiaolun Huang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Identification of potential biomarkers of long non-coding RNAs in neuropathic pain using bioinformatic analysis: A protocol for systematic review and meta-analysis.

Authors:  Yongzhi Fan; Na Li; Xianbao Yao
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

3.  Diabetic polyneuropathy with/out neuropathic pain in Mali: A cross-sectional study in two reference diabetes treatment centers in Bamako (Mali), Western Africa.

Authors:  Youssoufa Maiga; Salimata Diallo; Fatoumata Dite Nènè Konipo; Oumar Sangho; Modibo Sangaré; Seybou H Diallo; Saliou Mahamadou; Yann Péréon; Bernard Giumelli; Awa Coulibaly; Mariam Daou; Zoumana Traoré; Djeneba Sow Sylla; Mohamed Albakaye; Cheick Oumar Guinto; Madani Ouologem; Adama S Sissoko; Hamar A Traoré; Souleymane Papa Coulibaly; Philippe Damier; Nadine Attal; Julien Nizard
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

4.  Global Research on Neuropathic Pain Rehabilitation over the Last 20 Years.

Authors:  Xuan Su; Hao-Yu Hu; Chang Xu
Journal:  Neural Plast       Date:  2021-07-07       Impact factor: 3.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.